Albright Hereditary Osteodystrophy
8
1
3
2
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 75/100
25.0%
2 terminated out of 8 trials
50.0%
-36.5% vs benchmark
0%
0 trials in Phase 3/4
100%
2 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (8)
Glucose Homeostasis in Pseudohypoparathyroidism
Theophylline Treatment for Pseudohypoparathyroidism
Theophylline Treatment for Pseudohypoparathyroidism - Children 2-12 Years Old
Theophylline for Treatment of Pseudohypoparathyroidism
Albright Hereditary Osteodystrophy: Natural History, Growth, and Cognitive/Behavioral Assessments
Early-onset Obesity and Cognitive Impairment in Children With Pseudohypoparathyroidism
Energy Expenditure and Body Composition in Pseudohypoparathyroidism 1a
Theophylline as a Treatment for Children With Pseudohypoparathyroidism Type 1a (Albright Hereditary Osteodystrophy)